Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bausch Health Companies Inc.    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BAUSCH HEALTH : FDA APPROVES ORTHO DERMATOLOGICS LABELING FOR JUBLIA TOPICAL SOLUTION, 10%, IN PATIENTS AS YOUNG AS SIX YEARS OLD

share with twitter share with LinkedIn share with facebook
04/30/2020 | 05:33am EDT

LAVAL - Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for JUBLIA (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product's label to children six years of age and older.1

JUBLIA was first approved in June 2014 in patients 18 years and older.

'Onychomycosis is increasingly being seen in pediatrics - representing 15 percent of all nail dystrophies in children,'2 said Bill Humphries, president, Ortho Dermatologics. 'With nearly six years of real-world use since its initial approval to treat adults in 2014, JUBLIA has a demonstrated safety and efficacy profile, and we are pleased the FDA has recognized it as a valuable treatment option for children with toenail fungal infections.'

The safety, pharmacokinetics and efficacy of JUBLIA in patients ages six to 16 years old were evaluated in a multicenter, open-label, single-arm Phase 4 study that enrolled 62 patients with mild-to-severe onychomycosis. The primary objectives were to evaluate the safety of JUBLIA over the 52 weeks of the study in pediatric subjects with at least mild onychomycosis of the toenails, as well as the pharmacokinetics of JUBLIA at four weeks in pediatric subjects 12 to 16 years with moderate-to-severe onychomycosis of the toenails. Efficacy assessments included mycologic cure (fungus-free), complete cure (completely clear nails and fungus-free), and clinical efficacy (

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on BAUSCH HEALTH COMPANIES IN
07/08TSX edges higher as gold prices rise, virus concerns cap gains
RE
06/24BAUSCH HEALTH : Ortho dermatologics announces arazlo lotion, 0.045%, now availab..
AQ
06/24BAUSCH HEALTH COMPANIES INC : . - Ortho Dermatologics Launches ARAZLO Lotion, 0...
AQ
06/23BAUSCH HEALTH : Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, ..
AQ
06/18BAUSCH HEALTH : + LOMB ULTRA Silicone Hydrogel Contact Lenses Receive Approval i..
AQ
06/11BAUSCH HEALTH : Health Canada Issues Notice of Compliance for Bausch Health's DU..
AQ
06/09EXCLUSIVE : Chanel, Revlon, L'Oreal pivoting away from talc in some products
RE
06/09EXCLUSIVE : Chanel, Revlon, L'Oreal pivoting away from talc in some products
RE
06/05BAUSCH HEALTH : FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE Daily Dis..
AQ
05/28BAUSCH HEALTH : + Lomb Announces The European Launch Of LuxSmart And LuxGood Pre..
AQ
More news
Financials (USD)
Sales 2020 8 039 M - -
Net income 2020 -411 M - -
Net Debt 2020 22 174 M - -
P/E ratio 2020 -15,3x
Yield 2020 -
Capitalization 6 176 M 6 176 M -
EV / Sales 2019
EV / Sales 2020 3,53x
Nbr of Employees 21 700
Free-Float 99,4%
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES IN
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 27,30 $
Last Close Price 17,41 $
Spread / Highest target 268%
Spread / Average Target 56,8%
Spread / Lowest Target -19,6%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC.-41.81%6 176
JOHNSON & JOHNSON-0.45%375 087
ROCHE HOLDING AG5.75%300 427
MERCK & CO., INC.-14.95%193 674
NOVARTIS AG-10.77%192 177
PFIZER, INC.-10.13%187 920